Home » Stocks » XLRN

Acceleron Pharma, Inc. (XLRN)

Stock Price: $129.91 USD -0.36 (-0.28%)
Updated Mar 4, 2021 10:47 AM EST - Market open
Market Cap 8.06B
Revenue (ttm) 92.52M
Net Income (ttm) -166.03M
Shares Out 56.80M
EPS (ttm) -2.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 4
Last Price $129.91
Previous Close $130.27
Change ($) -0.36
Change (%) -0.28%
Day's Open 129.57
Day's Range 126.84 - 131.14
Day's Volume 51,727
52-Week Range 66.44 - 144.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 days ago

Acceleron (XLRN) reports a wider loss in the fourth quarter of 2020 on higher costs and lower revenues.

Benzinga - 6 days ago

Shares of Acceleron Pharma (NASDAQ:XLRN) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 115.91% year over year to ($0.95), w...

Business Wire - 6 days ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily ther...

Business Wire - 1 week ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily thera...

Zacks Investment Research - 1 week ago

Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 2 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 25, 2021 at 5:00 p.m. EST to discuss its...

Benzinga - 2 weeks ago

Bristol-Myers Squibb Co (NYSE: BMY) and its collaborating partner Acceleron Pharma Inc (NASDAQ: XLRN) have announced that Health Canada has approved Reblozyl (luspatercept for injection) to tr...

Other stocks mentioned: BMY
Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily thera...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that Habib Dable, Acceleron's President and Chief Executive Officer, will present a corporate overview du...

Investopedia - 2 months ago

These are the healthcare stocks with the best value, fastest growth, and most momentum for January 2021.

Other stocks mentioned: BIIB, BIO, CVS, HZNP, MRNA, PODD, QDEL, XLV
Zacks Investment Research - 2 months ago

The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.

Other stocks mentioned: EDIT, FATE, FOLD, RARE
Zacks Investment Research - 2 months ago

The U.S. healthcare sector emerged as one of the very few sectors that has been able to turn the misfortunes of COVID-19 pandemic to its advantage. The ongoing COVID-19 outbreak and an aging U...

Other stocks mentioned: BCRX, HALO, QDEL, TDOC
Zacks Investment Research - 2 months ago

Acceleron's (XLRN) investigational therapy sotatercept receives an Orphan designation in Europe for the treatment of patients with pulmonary arterial hypertension. Shares up.

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily ther...

Zacks Investment Research - 2 months ago

Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 3 months ago

The FDA grants orphan drug designation to Acceleron's (XLRN) ACE-1334 for the treatment of patients with systemic sclerosis.

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily ther...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therap...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therap...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therape...

Seeking Alpha - 3 months ago

Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 3 months ago

Acceleron Pharma's (XLRN) CEO Habib Dable On Q3 2020 Results - Quick Version Earnings Call Transcript

Zacks Investment Research - 3 months ago

Acceleron (XLRN) delivered earnings and revenue surprises of -20.00% and -17.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily thera...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily thera...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therap...

Zacks Investment Research - 4 months ago

Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insider Monkey - 4 months ago

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to ge...

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, November 5, 2020 at 5:00 p.m. EST to discuss its ...

Seeking Alpha - 4 months ago

Acceleron Pharma Plan For Sotatercept Adds To Buy Conviction

Business Wire - 5 months ago

MONTREAL & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. (NASDAQ:XLRN) announced today that Health Canada has approved REBLOZYL® (luspatercept)...

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.

Zacks Investment Research - 5 months ago

Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 6 months ago

The Reblozyl launch by partner Bristol-Myers Squibb is going well.

Kiplinger - 6 months ago

It's not uncommon for stocks that have significantly outperformed for several months to take a breather.

Other stocks mentioned: ALLO, DKNG, MYOK, PLUG, UTHR, YY
Seeking Alpha - 6 months ago

Acceleron Pharma's (XLRN) CEO Habib Dable on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Acceleron (XLRN) posts a narrower-than-expected Q2 loss owing to increased revenues.

Zacks Investment Research - 6 months ago

Acceleron (XLRN) delivered earnings and revenue surprises of 38.18% and 23.58%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 6 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.

Business Wire - 6 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.

Newsfile Corp - 7 months ago

New York, New York--(Newsfile Corp. - August 3, 2020) - Levi & Korsinsky announces it has commenced an investigation of Acceleron Pharma Inc.

Zacks Investment Research - 7 months ago

Acceleron (XLRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 7 months ago

Acceleron (XLRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 7 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.

Benzinga - 7 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Other stocks mentioned: SYNH, CLR
Business Wire - 7 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therap...

PRNewsWire - 7 months ago

NEW YORK, July 6, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acceleron Pharma Inc. ("Acceleron...

Zacks Investment Research - 7 months ago

Acceleron (XLRN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Kiplinger - 8 months ago

The pandemic has put the health care industry under a global spotlight.

Other stocks mentioned: AMGN, ANTM, BMY, GH, IOVA, IQV, MDT, VEEV, WST

About XLRN

Acceleron Pharma, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for ... [Read more...]

Industry
Biotechnology
IPO Date
Sep 19, 2013
CEO
Habib Dable
Employees
312
Stock Exchange
NASDAQ
Ticker Symbol
XLRN
Full Company Profile

Financial Performance

In 2020, XLRN's revenue was $92.52 million, an increase of 25.04% compared to the previous year's $73.99 million. Losses were -$166.03 million, 33.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for XLRN stock is "Buy." The 12-month stock price forecast is 145.42, which is an increase of 11.94% from the latest price.

Price Target
$145.42
(11.94% upside)
Analyst Consensus: Buy